{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T06:55:35Z","timestamp":1764053735464,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T00:00:00Z","timestamp":1620777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T00:00:00Z","timestamp":1620777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Alemtuzumab is a T cell depleting antibody agent used as induction immunosuppressant therapy in solid organ transplant recipients. In addition, it is being increasingly used to treat severe or glucocorticoid-resistant graft rejection. Despite the effectiveness of the treatment, severe adverse events have been reported related to alemtuzumab administration. We present a similar event illustrating the severity of this adverse drug reaction (ADR) and we highlight the structure causality assessment provides in approaching such a case.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>We report a case of life-threatening respiratory failure after alemtuzumab administration in a 17\u2009year old paediatric kidney transplant recipient. He developed near fatal severe respiratory and circulatory failure based on acute respiratory distress syndrome (ARDS) with diffuse alveolar oedema and haemoptysis hours after his second alemtuzumab administration. As it was questionable whether alemtuzumab could be regarded as the origin of his reaction and in order to assess the causality of this reaction as well as to structure clinical reasoning, we applied a widely used ADR probability scale to systematically review our case.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion and conclusions<\/jats:title><jats:p>Our case shows a severe ADR after alemtuzumab administration. It illustrates the importance of proper causality assessment, the structure it provides and the benefit of a clinical pharmacology consultation when a severe reaction is suspected to be an ADR. By taking our case as an example, we demonstrate the added value of structured causality assessment to clinical reasoning and in generating differential diagnoses.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12887-021-02698-w","type":"journal-article","created":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T06:05:29Z","timestamp":1620799529000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4927-2459","authenticated-orcid":false,"given":"Nori J. L.","family":"Smeets","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruud J. R.","family":"Eijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskia N.","family":"de Wildt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte M. H. H. T.","family":"Bootsma-Robroeks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,12]]},"reference":[{"issue":"2","key":"2698_CR1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1399-3046.2010.01432.x","volume":"15","author":"A Moudgil","year":"2011","unstructured":"Moudgil A, Martz K, Stablein DM, Puliyanda DP. Good outcome of kidney transplants in recipients of young donors: a NAPRTCS data analysis. Pediatr Transplant. 2011;15(2):167\u201371.","journal-title":"Pediatr Transplant"},{"issue":"4","key":"2698_CR2","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1542\/peds.2013-2775","volume":"133","author":"KJ Van Arendonk","year":"2014","unstructured":"Van Arendonk KJ, Boyarsky BJ, Orandi BJ, James NT, Smith JM, Colombani PM, et al. National trends over 25 years in pediatric kidney transplant outcomes. Pediatrics. 2014;133(4):594\u2013601. https:\/\/doi.org\/10.1542\/peds.2013-2775.","journal-title":"Pediatrics."},{"issue":"1","key":"2698_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1086\/340867","volume":"35","author":"S Husain","year":"2002","unstructured":"Husain S, Singh N. The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials. Clin Infect Dis. 2002;35(1):53\u201361. https:\/\/doi.org\/10.1086\/340867.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2698_CR4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00467-017-3826-x","volume":"34","author":"L Pape","year":"2019","unstructured":"Pape L. State-of-the-art immunosuppression protocols for pediatric renal transplant recipients. Pediatr Nephrol. 2019;34(2):187\u201394. https:\/\/doi.org\/10.1007\/s00467-017-3826-x.","journal-title":"Pediatr Nephrol"},{"key":"2698_CR5","unstructured":"Lemtrada, Summary of Product Characteristics. Sanofi 2018. Online available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lemtrada-epar-product-information_en.pdf."},{"issue":"2","key":"2698_CR6","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/petr.12048","volume":"17","author":"MM Kaabak","year":"2013","unstructured":"Kaabak MM, Babenko NN, Samsonov DV, Sandrikov VA, Maschan AA, Zokoev AK. Alemtuzumab induction in pediatric kidney transplantation. Pediatr Transplant. 2013;17(2):168\u201378. https:\/\/doi.org\/10.1111\/petr.12048.","journal-title":"Pediatr Transplant"},{"issue":"1","key":"2698_CR7","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1186\/s13104-019-4507-6","volume":"12","author":"T Holm\u00f8y","year":"2019","unstructured":"Holm\u00f8y T, Fevang B, Olsen DB, Spigset O, B\u00f8 L. Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis. BMC Res Notes. 2019;12(1):497. https:\/\/doi.org\/10.1186\/s13104-019-4507-6.","journal-title":"BMC Res Notes"},{"issue":"2","key":"2698_CR8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345. https:\/\/doi.org\/10.1038\/clpt.1981.154.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2698_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.23876\/j.krcp.20.003","volume":"39","author":"HJ Jeong","year":"2020","unstructured":"Jeong HJ. Diagnosis of renal transplant rejection: Banff classification and beyond. Kidney Res Clin Pract. 2020;39(1):17\u201331. https:\/\/doi.org\/10.23876\/j.krcp.20.003.","journal-title":"Kidney Res Clin Pract"},{"issue":"9","key":"2698_CR10","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/j.1365-2036.2008.03655.x","volume":"27","author":"M Garc\u00eda-Cort\u00e9s","year":"2008","unstructured":"Garc\u00eda-Cort\u00e9s M, Lucena MI, Pachkoria K, Borraz Y, Hidalgo R, Andrade RJ. Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Aliment Pharmacol Ther. 2008;27(9):780\u20139. https:\/\/doi.org\/10.1111\/j.1365-2036.2008.03655.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2698_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2165\/00002018-200831010-00003","volume":"31","author":"TB Agbabiaka","year":"2008","unstructured":"Agbabiaka TB, Savovi\u0107 J, Ernst E. Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf. 2008;31(1):21\u201337. https:\/\/doi.org\/10.2165\/00002018-200831010-00003.","journal-title":"Drug Saf"},{"issue":"1","key":"2698_CR12","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1186\/s12883-020-01934-7","volume":"20","author":"A Bayas","year":"2020","unstructured":"Bayas A, Menacher M, Schwaiblmair M, M\u00e4rkl B, Naumann M. Alemtuzumab-associated diffuse alveolar damage - a case report. BMC Neurol. 2020;20(1):357. https:\/\/doi.org\/10.1186\/s12883-020-01934-7.","journal-title":"BMC Neurol"},{"key":"2698_CR13","doi-asserted-by":"publisher","first-page":"101450","DOI":"10.1016\/j.msard.2019.101450","volume":"37","author":"A Bianco","year":"2020","unstructured":"Bianco A, Mari PV, Larici AR, Lucchini M, Nociti V, Losavio FA, et al. Alemtuzumab-induced lung injury in multiple sclerosis: learning from adversity in three patients. Mult Scler Relat Disord. 2020;37:101450. https:\/\/doi.org\/10.1016\/j.msard.2019.101450.","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"2698_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40360-018-0267-5","volume":"19","author":"AZ Myro","year":"2018","unstructured":"Myro AZ, Bjerke G, Zarnovicky S, Holmoy T. Diffuse alveolar hemorrhage during alemtuzumab infusion in a patient with multiple sclerosis: a case report. BMC Pharmacol Toxicol. 2018;19(1):75. https:\/\/doi.org\/10.1186\/s40360-018-0267-5.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"6","key":"2698_CR15","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1378\/chest.07-2354","volume":"133","author":"A Sachdeva","year":"2008","unstructured":"Sachdeva A, Matuschak GM. Diffuse alveolar hemorrhage following alemtuzumab. Chest. 2008;133(6):1476\u20138. https:\/\/doi.org\/10.1378\/chest.07-2354.","journal-title":"Chest."},{"issue":"1","key":"2698_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.transproceed.2014.10.037","volume":"47","author":"W Tahir","year":"2015","unstructured":"Tahir W, Hakeem A, Baker R, Ahmad N. Diffuse alveolar haemorrhage: a fatal complication after alemtuzumab induction therapy in renal transplantation. Transplant Proc. 2015;47(1):151\u20134. https:\/\/doi.org\/10.1016\/j.transproceed.2014.10.037.","journal-title":"Transplant Proc"},{"key":"2698_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.msard.2017.03.001","volume":"14","author":"K Yann","year":"2017","unstructured":"Yann K, Jackson F, Sharaf N, Mihalova T, Talbot P, Rog D, et al. Acute respiratory distress syndrome following alemtuzumab therapy for relapsing multiple sclerosis. Mult Scler Relat Disord. 2017;14:1\u20133. https:\/\/doi.org\/10.1016\/j.msard.2017.03.001.","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"2698_CR18","doi-asserted-by":"publisher","first-page":"718","DOI":"10.4187\/respcare.05591","volume":"62","author":"IM Cheifetz","year":"2017","unstructured":"Cheifetz IM. Pediatric ARDS. Respir Care. 2017;62(6):718\u201331.","journal-title":"Respir Care"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-021-02698-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-021-02698-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-021-02698-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T16:32:05Z","timestamp":1699029125000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-021-02698-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,12]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2698"],"URL":"https:\/\/doi.org\/10.1186\/s12887-021-02698-w","relation":{},"ISSN":["1471-2431"],"issn-type":[{"type":"electronic","value":"1471-2431"}],"subject":[],"published":{"date-parts":[[2021,5,12]]},"assertion":[{"value":"28 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient and his parents gave permission to publish this work, no institutional review board approval was obtained. Written informed consent of the patient and his parents was obtained and is available upon request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"229"}}